 Ascertainment of cardiovascular (CV) outcomes via physician review of medical records using a standardized case definition aims to maximize data quality,

Slides:



Advertisements
Similar presentations
Allen Jeremias MD MSc, Sanjay Kaul MD, Luis Gruberg MD, Todd K. Rosengart MD, David L. Brown MD Divisions of Cardiovascular Medicine and Cardiothoracic.
Advertisements

Hospital Volume and 30-day Mortality following Hospitalization for Acute Myocardial Infarction and Heart Failure Joseph S. Ross, MD, MHS Mount Sinai School.
IntroductionMethods (continued)Results (continued)Strengths and Limitations Background Pharmacologic treatments are efficacious in reducing post-myocardial.
KAREN L. WALKER MS JONATHAN J. SHUSTER PHD THOMAS M. BEAVER MD, MPH DIVISION OF THORACIC AND CARDIOVASCULAR SURGERY DIVISION OF BIOSTATISTICS UNIVERSITY.
Technology Diffusion, Hospital Variation, and Racial Disparities Among Elderly Medicare Beneficiaries: Peter W. Groeneveld, MD, MS Sara B. Laufer,
Validation of Acute Stroke in Medicare Data against WHI Kamakshi Lakshminarayan, MD, PhD presented by Dale Burwen, MD, MPH WHI Investigators Meeting May.
Inappropriate clopidogrel adherence explains stent related adverse outcomes Leonardo Tamariz, MD, MPH University of Miami.
Can administrative data increase the practicality of clinical trials? An example from the Women’s Health Initiative Garnet Anderson Fred Hutchinson Cancer.
Women’s Health Initiative Scientific Symposium May
RACIAL DISPARITIES IN PRESCRIPTION DRUG UTILIZATION AN ANALYSIS OF BETA-BLOCKER AND STATIN USE FOLLOWING HOSPITALIZATION FOR ACUTE MYOCARDIAL INFARCTION.
1 Canadian Institute for Health Information. Hospital Care for Heart Attacks Among First Nations, Inuit and Métis Released January 31,
1 Comparing Zero Coronary Artery Calcium With Other Negative Risk Factors for Coronary Heart Disease A Novel Methodology: Risk-Adjusted Negative Likelihood.
National Report Card on Hospital care for heart disease in Indigenous Australia Traven Lea, National Manager, Aboriginal and Torres Strait Islander Program.
Capture of acute myocardial infarctions occurring at non-VA hospitals by outpatient, VA Healthcare System ICD-9 codes CONCLUSIONS 1.NVH records can be.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
1 Terri Conner,PhD Nybeck Analytics Partnership for Patients 14 th May 2012 USE OF MEDICARE DIAGNOSIS AND PROCEDURE CODES TO IMPROVE DETECTION OF SURGICAL.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
What Is Peripheral Vascular Disease? Daniel B. Walsh, M.D. Professor of Surgery, Section of Vascular Surgery Vice-Chair, Department of Sugery Dartmouth-Hitchcock.
Agency for Healthcare Research and Quality Advancing Excellence in Health Care Improving Administrative Data for Public Reporting Anne Elixhauser.
Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.
10 Points to Remember on the Assessment of Cardiovascular RiskAssessment of Cardiovascular Risk Summary Prepared by Melvyn Rubenfire, MD.
BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.
Leapfrog’s “Survival Predictor”: Composite Measures for Predicting Hospital Surgical Mortality May 7, 2008.
Antiplatelet Therapy Use and the Risk of Venous Thromboembolic Events in the Double-Blind Raloxifene Use for the Heart (RUTH) Trial C. Duvernoy 1, A. Yeo.
Influence of Comorbid Depression and Antidepressant Treatment on Mortality for Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease by SSDI-eligibility.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
National Heart, Lung, and Blood Institute Women’s Health Initiative Branch Jacques Rossouw, MD Chief, WHI Branch Program for Prevention and Population.
#735 KA Lichtenstein 1, C Armon 2, K Buchacz 3, AC Moorman 3, KC Wood 2, JT Brooks 3, and the HOPS Investigators 1 University of Colorado Health Sciences.
FDA Presentation ODAC Meeting July NDA Applicant: Eli Lilly Evista ® (Raloxifene Hydrochloride)
LEADING RESEARCH… MEASURES THAT COUNT Challenges of Studying Cardiovascular Outcomes in ADHD Elizabeth B. Andrews, MPH, PhD, VP, Pharmacoepidemiology and.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
Higher Incidence of Venous Thromboembolism (VTE) in the Outpatient versus Inpatient Setting Among Patients with Cancer in the United States Khorana A et.
Health Services Research SIG October 2010 – September 2011 Newly established SIG (no previous WHI focus on health services research or claims data) About.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
1 Statistical Review of the Observational Studies of Aprotinin Safety Part II: The i3 Drug Safety Study CRDAC and DSaRM Meeting September 12, 2007 P. Chris.
A Comparison of Quality of Care in General Hospitals, Specialty Hospitals, and Ambulatory Surgery Centers Cheryl Fahlman, PhD Phil Kletke, PhD Chuck Wentworth,
Inpatient Quality Reporting In Colorado Sept HCUP User Group Meeting.
Late Open Artery Hypothesis Jason S. Finkelstein, M.D. Tulane University Medical Center 2/24/03.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Peripheral Artery Disease in Orthopaedic Patients with Asymptomatic Popliteal Artery Calcification on Plain X-ray Adam Podet, MS; Julia Volaufova, phD,;
Journal Club Julie Shah, MD Milton S Hershey Medical Center Penn State University.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Menopausal Hormone Therapy and Health Outcomes During.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Frequency and Practice-Level Variation in Inappropriate.
No conflicts of interest or financial ties to disclose.
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Scope of Coronary Heart Disease in Patients With.
Date of download: 7/5/2016 From: Validation of the Appropriate Use Criteria for Coronary Angiography: A Cohort Study Ann Intern Med. 2015;162(8):
Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.
Journal Club Curriculum-Study designs. Objectives  Distinguish between the main types of research designs  Randomized control trials  Cohort studies.
Longest Follow-up After Implantation of a Self-Expanding Repositionable Transcatheter Aortic Valve: Final Follow-up of the Evolut R CE Study Stephen Brecker,
US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.
Journal of the American College of Cardiology
Quality of Electronic Emergency Department Data: How Good Are They?
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Comparative Efficiency of Exercise Stress Testing With.
Women’s Health Initiative Scientific Symposium May
PCI related in-hospital mortality based on race and gender in the USA
Volume 1: Chronic Kidney Disease
Andre Lamy on behalf of the COMPASS Investigators
Jeff Macemon Waikato Cardiothoracic Unit
Baseline characteristics of HPS participants by prior diabetes
Clinical Event Classification: Strategies and Practices
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Why surgery won the SYNTAX trial and why it matters
Poster WP41; Contact: David A. Katz,
Recent Temporal Changes in Atherosclerotic Cardiovascular Diseases in Ontario: Clinical and Health Systems Impact  Jack V. Tu, MD, PhD, Anam M. Khan,
Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.
Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.
Presentation transcript:

 Ascertainment of cardiovascular (CV) outcomes via physician review of medical records using a standardized case definition aims to maximize data quality, but is resource intensive.  Adjudication of CV outcomes is limited to a quarter of Women’s Health Initiative (WHI) participants starting in  To assess whether Medicare data can be used to reliably identify CV outcomes in WHI.  Four projects, focusing on coronary heart disease (CHD), stroke, venous thromboembolism (VTE), and peripheral artery disease (PAD), contributed to this comparison.  Study population  WHI participants with fee-for-service Medicare coverage at baseline ( )  Some analyses also included participants who aged in  Excluded participants who had WHI outcome of interest prior to entering Medicare  Medicare data through 2007 (CHD, stroke, PAD) or 2010 (VTE) were used  Project specific cohorts selected based on availability of WHI adjudicated outcomes and other factors  Divided into training (data shown) and test sets  Coding algorithms  Evaluated and modified as needed in training set  Used hospital claims (MedPAR file) and ICD-9-CM discharge diagnoses (in any position) and procedure codes  Some analyses also used CPT/HCPCS codes from Carrier/Outpatient claims files  Performed person-based analysis  Assessed agreement  Kappa statistic  Sensitivity (SN), specificity (SP), positive predictive value (PPV), negative predictive value (NPV)  WHI diagnosis defined as “gold standard”  Assessed reasons for disagreement  Additional analyses excluded records that were not informative with regard to performance of Medicare data  E.g., WHI medical record not received Dale R. Burwen 1, Garnet Anderson 2, Dominic Cirillo 3, Mark Hlatky 4, Kamakshi Lakshminarayan 5, Joseph Larson 2, Marian Limacher 6, Karen Margolis 7, Matthew Mell 4, Mary Pettinger 2, Ross Prentice 2, Roberta Ray 2, Beth Virnig 5, Chunyuan Wu 2, Jacques E. Rossouw 1 1 National Heart, Lung, and Blood Institute, Bethesda, MD; 2 Fred Hutchinson Cancer Research Center, Seattle, WA; 3 University of Iowa, Iowa City, IA; 4 Stanford University, Stanford, CA; 5 University of Minnesota, Minneapolis, MN; 6 University of Florida, Gainesville, FL; 7 HealthPartners, Minneapolis, MN Comparison of Medicare Claims vs. Physician Adjudication for Identifying Cardiovascular Outcomes in the Women’s Health Initiative OBJECTIVE METHODS RESULTS SUMMARY AND CONCLUSION BACKGROUND Table 2. Sensitivity of Medicare Data for Identifying WHI Outcomes. Table 3. Kappa Statistic Comparing Agreement Between Medicare and WHI Outcomes. Table 1. Positive Predictive Value of Medicare Data for Identifying WHI Outcomes. Condition*MICABGPCIStrokeVTECarotidAAALE PAD Total participants with Medicare events PPV (%), All WHI hospitalization reported † WHI hospitalization adjudicated ‡ § 82 §  Among participants with an outcome in both WHI and Medicare data, dates were within +/-30 days for most events  Examples: 96% for Stroke; 94% for MI; 85% for lower extremity (LE) PAD  Details for Stroke (n=505):  83% on same date; 88% within +/- 1 day; 91% within +/-3 days; 95% within +/- 7 days; 96% within +/- 30 days  Range (WHI date – Medicare date) to 682 days  Specificity and NPV were >98% for all conditions; PPV, sensitivity, and kappa are provided in Tables 1-3 * MI, myocardial infarction; CABG, coronary artery bypass graft surgery; PCI, percutaneous coronary intervention; VTE, venous thromboembolism (including deep venous thrombosis and pulmonary embolism); Carotid, carotid artery treatment procedure; AAA, abdominal aortic aneurysm treatment procedure; LE PAD, lower extremity peripheral artery disease treatment procedure † Participants with events in Medicare data only were excluded if no WHI hospitalization recorded within +/-30 days ‡ Participants with events in Medicare data only were excluded if no WHI hospitalization adjudicated within +/-30 days §Further evaluation by reviewing Medicare physician claims and selected medical records yielded PPV estimate of 91%- 94% for AAA and 92%-95% for LE PAD ACKNOWLEDGMENTS  Key reason for a Medicare event without WHI match was lack of WHI report of hospitalization  E.g., Inadequate recall; disability/death and lack of proxy report  Even if hospitalization reported to WHI, not all were adjudicated  E.g., No medical records received; reported reason for hospitalization did not meet criteria for adjudication  Limiting analysis to Medicare events that could be evaluated with WHI adjudicated records increased PPV  Some AAA and LE PAD procedures found in Medicare hospital claims but not WHI data were corroborated by Medicare physician claims or review of selected medical records (data not shown)  Estimated PPV was high  Test set results (data not shown) were similar to training set results  CHD, Stroke, PAD (VTE pending)  Although we defined WHI outcomes as the gold standard, ascertainment of events depends on reporting of hospitalization by participants  This reporting is similar across trial arms, but can be incomplete  The adjudication process ensures that virtually all WHI identified events are true  Medicare data miss some events in WHI, yet record others not identified in WHI  The associated PPV is imperfect, however  PPV is high for CABG, PCI and carotid procedures (when analysis was limited to participants with an adjudicated medical record)  We estimate it may be similar or almost as high for AAA and LE PAD  PPV was slightly lower but reasonably high for MI and stroke  For VTE, a relatively larger proportion of hospitalizations reported were not adjudicated  Therefore more caution is needed in generalizing from the subset adjudicated, and the best estimate of the PPV may be lower  Additional VTE coding algorithms are being tested  We thank the other members of the working groups for the 4 contributing projects (CHD, stroke, VTE, PAD). We gratefully acknowledge the dedication of the WHI participants, and investigators and staff who have contributed to the WHI.  The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN C, HHSN C, HHSN C, HHSN C, HHSN C, and HHSN C. Condition*MICABGPCIStrokeVTECarotidAAALE PAD Total participants included in analysis Kappa, All WHI hospitalization reported † WHI hospitalization adjudicated ‡ Condition*MICABGPCIStrokeVTECarotidAAALE PAD Total participants with WHI events Sensitivity (%), All